Effects of Salvinorin A on Brain Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03418714|
Recruitment Status : Recruiting
First Posted : February 1, 2018
Last Update Posted : January 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Drug Effect||Drug: Salvinorin A||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Masking Description:||Participants will not be aware of exact doses salvinorin A (i.e. they will be told they may receive placebo or up to a moderately high dose of of salvinorin A).|
|Official Title:||Effects of Salvinorin A on Brain Function|
|Actual Study Start Date :||December 14, 2017|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||February 2019|
Experimental: Salvinorin A administration
All volunteers will be assigned to the salvinorin A administration arm.
Drug: Salvinorin A
Salvinorin A, blinded doses
Other Name: salvia, salvia divinorum
- Changes in brain activity (fMRI) [ Time Frame: Continuous for 20 minutes after drug administration ]Changes in brain activity will be assessed using blood-oxygenation level dependent [BOLD] techniques.
- Changes in brain connectivity (fMRI) [ Time Frame: Continuous for 20 minutes after drug administration ]Changes in within- and between-network connectivity strength of several brain networks will be assessed via analysis of blood-oxygenation level dependent [BOLD] data.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03418714
|Contact: John Clifton, B.A.||email@example.com|
|United States, Maryland|
|Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center||Recruiting|
|Baltimore, Maryland, United States, 21224|
|Contact: John Clifton, B.A. 410-550-3074 firstname.lastname@example.org|
|Principal Investigator:||Frederick S Barrett, Ph.D.||Johns Hopkins University|